Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04472429




Registration number
NCT04472429
Ethics application status
Date submitted
13/07/2020
Date registered
15/07/2020
Date last updated
6/06/2024

Titles & IDs
Public title
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
Scientific title
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
Secondary ID [1] 0 0
INCMGA 0012-303
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Squamous Cell Carcinoma of the Anal Canal 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - carboplatin
Treatment: Drugs - paclitaxel
Treatment: Drugs - retifanlimab

Placebo Comparator: Group A : carboplatin+paclitaxel+placebo - Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and placebo on Day 1 of each 28 day cycle

Experimental: Group B : carboplatin+paclitaxel+retifanlimab - Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and retifanlimab on Day 1 of each 28 day cycle


Treatment: Drugs: carboplatin
carboplatin will be administered intravenous on Day 1 of each 28 day cycle

Treatment: Drugs: paclitaxel
paclitaxel will be administered intravenous on Days 1,8, and 15 of each 28 day cycle

Treatment: Drugs: retifanlimab
retifanlimab will be administered intravenous on Day 1 of each 28 day cycle
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS)
Timepoint [1] 0 0
up to 4.5 years
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Up to 4.5 years
Secondary outcome [2] 0 0
Overall Response Rate (ORR)
Timepoint [2] 0 0
Up to 4.5 years
Secondary outcome [3] 0 0
Duration of Response (DOR)
Timepoint [3] 0 0
Up to 4.5 years
Secondary outcome [4] 0 0
Disease Control Rate(DCR)
Timepoint [4] 0 0
Up to 4.5 years
Secondary outcome [5] 0 0
Number of treatment-emergent adverse events
Timepoint [5] 0 0
Up to 4.5 years
Secondary outcome [6] 0 0
Cmax of retifanlimab when administered with chemotherapy
Timepoint [6] 0 0
Up to 4.5 years
Secondary outcome [7] 0 0
tmax of retifanlimab when administered with chemotherapy
Timepoint [7] 0 0
Up to 4.5 years
Secondary outcome [8] 0 0
Cmin of retifanlimab when administered with chemotherapy
Timepoint [8] 0 0
Up to 4.5 years
Secondary outcome [9] 0 0
AUC0-t of retifanlimab when administered with chemotherapy
Timepoint [9] 0 0
Up to 4.5 years

Eligibility
Key inclusion criteria
- Able to comprehend and willing to sign a written ICF for the study.

- Are 18 years of age or older (or as applicable per local country requirements).

- Histologically or cytologically verified, inoperable locally recurrent or
metastatic SCAC.

- No prior systemic therapy other than the following: a. Chemotherapy administered
concomitantly with radiotherapy as a radiosensitizing agent is permitted.

b. Prior neoadjuvant or adjuvant therapy if completed = 6 months before study
entry.

- Has measurable disease per RECIST v1.1 as determined by local site
investigator/radiology assessment. Tumor lesions situated in a previously
irradiated area, or in an area subjected to other loco-regional therapy, are
usually not considered measurable unless there has been demonstrated progression
in the lesion.

- Able and willing to provide adequate tissue sample and whole blood sample with
central testing result prior to randomization. Biopsy for archival samples should
have occurred within 9 months prior to randomization.

- ECOG performance status 0 to 1.

- If HIV-positive, then must be stable as defined by: a. CD4+ count = 200/µL, b.
Undetectable viral load per standard of care assay, c. Receiving antiretroviral
therapy (ART/HAART) for at least 4 weeks prior to study enrollment, and have not
experienced any HIV-related opportunistic infection for at least 4 weeks prior to
study enrollment.

- Willingness to avoid pregnancy or fathering children
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Has received prior PD-(L)1 directed therapy

- Has received prior radiotherapy with or without radiosensitizing chemotherapy within
28 days of Cycle 1 Day 1 except for palliative radiation (30 Gy or less) which is
restricted for 14 days of Cycle 1 Day 1 (note: all toxicities associated should have
resolved to Grade = 1).

- Participants with laboratory outside of the protocol defined ranges.

- History of second malignancy within 3 years (with exceptions).

- Clinically significant pulmonary, cardiac, gastrointestinal or autoimmune disorders.

- Active bacterial, fungal, or viral infections, including hepatitis A, B, and C and IV
antibiotic use within 7 days of Cycle 1 Day 1.

- Receipt of a live vaccine within 28 days of planned start of study therapy.

- History of organ transplant, including allogeneic stem cell transplantation.

- Known active CNS metastases and/or carcinomatous meningitis.

- Known hypersensitivity to platinum, paclitaxel, another monoclonal antibody, or any of
the excipients that cannot be controlled with standard measures (eg, antihistamines,
corticosteroids).

- Participant is pregnant or breastfeeding.

- Current use of protocol defined prohibited medication.

- Has pre-existing peripheral neuropathy that is = Grade 2 by CTCAE v5.

- Inability or unlikely, in the opinion of the investigator, to comply with the Protocol
requirements

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/01/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
27/10/2024
Actual
Sample size
Target
Accrual to date
Final
308
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Recruitment hospital [1] 0 0
Princess Alexandra Hospital Australia - Woolloongabba
Recruitment hospital [2] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [3] 0 0
Monash Medical Centre Clayton - Clayton
Recruitment postcode(s) [1] 0 0
04102 - Woolloongabba
Recruitment postcode(s) [2] 0 0
5042 - Bedford Park
Recruitment postcode(s) [3] 0 0
03168 - Clayton
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Louisiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Minnesota
Country [7] 0 0
United States of America
State/province [7] 0 0
Texas
Country [8] 0 0
United States of America
State/province [8] 0 0
Virginia
Country [9] 0 0
Belgium
State/province [9] 0 0
Antwerpen
Country [10] 0 0
Belgium
State/province [10] 0 0
Bruxelles
Country [11] 0 0
Denmark
State/province [11] 0 0
Herlev
Country [12] 0 0
Denmark
State/province [12] 0 0
Vejle
Country [13] 0 0
France
State/province [13] 0 0
Angers Cedex 2
Country [14] 0 0
France
State/province [14] 0 0
Besançon
Country [15] 0 0
France
State/province [15] 0 0
Bordeaux Cedex
Country [16] 0 0
France
State/province [16] 0 0
Lyon
Country [17] 0 0
France
State/province [17] 0 0
Marseille Cedex 5
Country [18] 0 0
France
State/province [18] 0 0
Montpellier
Country [19] 0 0
France
State/province [19] 0 0
Nice
Country [20] 0 0
France
State/province [20] 0 0
Paris Cedex 13
Country [21] 0 0
France
State/province [21] 0 0
Poitiers Cedex
Country [22] 0 0
France
State/province [22] 0 0
Rennes Cedex 09
Country [23] 0 0
France
State/province [23] 0 0
Rouen Cedex
Country [24] 0 0
France
State/province [24] 0 0
Saint Herblain
Country [25] 0 0
France
State/province [25] 0 0
Strasbourg
Country [26] 0 0
France
State/province [26] 0 0
Toulouse Cedex 9
Country [27] 0 0
France
State/province [27] 0 0
Villejuif Cedex
Country [28] 0 0
Germany
State/province [28] 0 0
Bonn
Country [29] 0 0
Germany
State/province [29] 0 0
Dresden
Country [30] 0 0
Germany
State/province [30] 0 0
Hamburg
Country [31] 0 0
Italy
State/province [31] 0 0
Milano
Country [32] 0 0
Italy
State/province [32] 0 0
Milan
Country [33] 0 0
Italy
State/province [33] 0 0
Monserrato
Country [34] 0 0
Italy
State/province [34] 0 0
Napoli
Country [35] 0 0
Italy
State/province [35] 0 0
Padova
Country [36] 0 0
Italy
State/province [36] 0 0
Pisa
Country [37] 0 0
Italy
State/province [37] 0 0
Rimini
Country [38] 0 0
Italy
State/province [38] 0 0
San Giovanni Rotondo
Country [39] 0 0
Italy
State/province [39] 0 0
Torrette
Country [40] 0 0
Japan
State/province [40] 0 0
Chuo-ku
Country [41] 0 0
Japan
State/province [41] 0 0
Fukuoka-shi
Country [42] 0 0
Japan
State/province [42] 0 0
Hidaka-shi
Country [43] 0 0
Japan
State/province [43] 0 0
Nagoya-shi
Country [44] 0 0
Japan
State/province [44] 0 0
Osaka-shi
Country [45] 0 0
Japan
State/province [45] 0 0
Sendai-shi
Country [46] 0 0
Japan
State/province [46] 0 0
Shinjuku-ku
Country [47] 0 0
Norway
State/province [47] 0 0
Bergen
Country [48] 0 0
Norway
State/province [48] 0 0
Oslo
Country [49] 0 0
Puerto Rico
State/province [49] 0 0
San Juan
Country [50] 0 0
Spain
State/province [50] 0 0
A Coruña
Country [51] 0 0
Spain
State/province [51] 0 0
Barcelona
Country [52] 0 0
Spain
State/province [52] 0 0
Madrid
Country [53] 0 0
Spain
State/province [53] 0 0
Palma de Mallorca
Country [54] 0 0
Spain
State/province [54] 0 0
Sevilla
Country [55] 0 0
Spain
State/province [55] 0 0
Zaragoza
Country [56] 0 0
Sweden
State/province [56] 0 0
Goteborg
Country [57] 0 0
Sweden
State/province [57] 0 0
Lund
Country [58] 0 0
Sweden
State/province [58] 0 0
Stockholm
Country [59] 0 0
United Kingdom
State/province [59] 0 0
Brighton
Country [60] 0 0
United Kingdom
State/province [60] 0 0
Cambridge
Country [61] 0 0
United Kingdom
State/province [61] 0 0
Guildford
Country [62] 0 0
United Kingdom
State/province [62] 0 0
Hull
Country [63] 0 0
United Kingdom
State/province [63] 0 0
Leeds
Country [64] 0 0
United Kingdom
State/province [64] 0 0
London
Country [65] 0 0
United Kingdom
State/province [65] 0 0
Manchester
Country [66] 0 0
United Kingdom
State/province [66] 0 0
Oxford
Country [67] 0 0
United Kingdom
State/province [67] 0 0
Preston
Country [68] 0 0
United Kingdom
State/province [68] 0 0
Sutton
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Truro

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Incyte Corporation
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study
that will enroll participants with inoperable locally recurrent or metastatic SCAC not
previously treated with systemic chemotherapy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04472429
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04472429